Watching
$Indaptus Therapeutics(INDP.US$ Indaptus Therapeutics To Present New Positive Data On Decoy20 At Next-Gen Immuno-Oncology Conference
Benzinga· 2 mins ago
Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company's lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024.
Dr. Waltzman will present preliminary results from the Company's ongoing Phase 1 study of Decoy20, an intravenous treatment using killed bacteria designed to broadly stimulate the immune system, in patients with advanced solid tumors.
Benzinga· 2 mins ago
Indaptus Therapeutics, Inc, (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on the Company's lead product candidate, Decoy20, at the 7th Annual Next-Gen Immuno-Oncology Conference in Boston on June 20-21, 2024.
Dr. Waltzman will present preliminary results from the Company's ongoing Phase 1 study of Decoy20, an intravenous treatment using killed bacteria designed to broadly stimulate the immune system, in patients with advanced solid tumors.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
70125061 : Volume blows
TrytosaveabitOP 70125061: 2 things! PM and the other is the conference isn’t until June 20th! GL
买跌不追涨 : not active
TrytosaveabitOP 买跌不追涨: Didn’t expect it to be until June 20th or so!